We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

27 hedge funds and large institutions have $123M invested in MoonLake Immunotherapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 2

9% more capital invested

Capital invested by funds: $113M → $123M (+$10.6M)

1.19% more ownership

Funds ownership: 95.77% → 96.95% (+1.2%)

40% less funds holding

Funds holding: 45 → 27 (-18)

72% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 25

Holders
27
Holders Change
-18
Holders Change %
-40%
% of All Funds
0.43%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
8
Reduced
2
Closed
25
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
+$28.4M
2
BCM
Beryl Capital Management
California
+$4.57M
3
6CM
683 Capital Management
New York
+$1.99M
4
WAM
Weiss Asset Management
Massachusetts
+$1.62M
5
AWG
Alpha Wave Global
New York
+$1.4M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$10M
2
BC
Boxer Capital
California
-$3.96M
3
OCA
Octagon Capital Advisors
New York
-$3.96M
4
CS
Credit Suisse
Switzerland
-$3.68M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$3.17M
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$33.3M +$28.4M +2,850,000 +663%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$13.2M – – –
BlackRock
3
BlackRock
New York
$8.24M – – –
6CM
4
683 Capital Management
New York
$7.9M +$1.99M +200,000 +34%
Citadel Advisors
5
Citadel Advisors
Florida
$7.76M +$129K +12,959 +2%
Marshall Wace
6
Marshall Wace
United Kingdom
$7.26M +$1.2M +120,968 +23%
SCA
7
STALEY CAPITAL ADVISERS
Pennsylvania
$6.35M – – –
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$6.29M -$1.8M -180,671 -24%
BCM
9
Beryl Capital Management
California
$5.1M +$4.57M +459,243 New
AWG
10
Alpha Wave Global
New York
$4.49M +$1.4M +141,047 +46%
APM
11
Avidity Partners Management
Texas
$4.44M – – –
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$3.74M – – –
TCM
13
Tekla Capital Management
Massachusetts
$2.77M – – –
EC
14
EcoR1 Capital
California
$2.22M – – –
WAM
15
Weiss Asset Management
Massachusetts
$1.97M +$1.62M +162,510 +1,083%
IPCP
16
Iron Park Capital Partners
New York
$1.79M +$1.17M +117,218 +188%
Millennium Management
17
Millennium Management
New York
$1.65M +$920K +92,490 +166%
CCM
18
Consonance Capital Management
New York
$1.52M -$129K -13,000 -9%
Jane Street
19
Jane Street
New York
$726K +$651K +65,437 New
PMAM
20
Picton Mahoney Asset Management
Ontario, Canada
$700K – – –
FTCM
21
Fir Tree Capital Management
New York
$619K +$615K +61,866 New
OAC
22
OMERS Administration Corp
Ontario, Canada
$513K +$460K +46,247 New
MWM
23
Meridian Wealth Management
Kentucky
$467K – – –
Nomura Holdings
24
Nomura Holdings
Japan
$239K – – –
E
25
Ergoteles
New York
$162K +$145K +14,613 New
1
2 3

MLTX Hedge Fund Activity: Q1 2022 in Review

27 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q1 2022, worth a combined $123M — up 9.4% from $113M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of MLTX and 7 opened new positions — a net loss of 18 holders — while 2 trimmed existing stakes and 8 added.

The largest buyer was Cormorant Asset Management, adding an estimated $28.4M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $10M sold.

  • 27 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q1 2022, down from 45 in Q4 2021.
  • Funds reported $123M of MoonLake Immunotherapeutics stock for Q1 2022, up 9.4% quarter-over-quarter.
  • 7 funds opened new MoonLake Immunotherapeutics positions in Q1 2022 and 25 closed out, a net change of -18 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q1 2022 was Cormorant Asset Management, an estimated $28.4M added.
  • The largest MoonLake Immunotherapeutics seller in Q1 2022 was Adage Capital Partners, an estimated $10M sold.

Based on aggregated 13F filings for Q1 2022.